68Gallium-FAPI PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases

Launched by UNIVERSITY HOSPITAL, BREST · Feb 16, 2024

Keywords

ClinConnect Summary

This clinical trial is looking into a new imaging technique using a special agent called 68Ga-FAPI to help doctors better understand and diagnose chronic inflammatory diseases, such as rheumatoid arthritis, liver fibrosis, and systemic lupus. By combining positron emission tomography (PET) and computed tomography (CT), researchers hope to see if this new imaging method can improve how accurately these conditions are diagnosed and monitored over time. The study will focus on 13 different health issues to see how useful this technology could be in everyday medical care.

To join the study, participants need to be at least 18 years old and have one of the specific conditions being examined. Women who can become pregnant will need to have a negative pregnancy test and agree to use contraception during the study. Importantly, the trial is not yet recruiting participants, but when it begins, those who take part can expect to undergo imaging tests that may help advance our understanding of these diseases and improve future treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient aged 18 or over.
• • Affected by one of the pathologies concerned by the study (see Table 4)
• • Satisfying the consensus classification criteria for the pathology (Table 3).
• • Satisfying the corresponding clinical situation (Table 3).
• • Negative urine pregnancy test for women of childbearing age.
• • Affiliated with or benefiting from social security.
• • Informed consent (personally dated and) signed by the participant or any representatives (impartial witness/trusted person).
• Exclusion Criteria:
• • Patients unable to consent.
• • Incapacitated adults.
• • Pregnant or breastfeeding women.
• • Patients refusing to participate in research.
• • Known active cancer.
• • Women of childbearing potential unwilling to use appropriate contraception (definitions given in Annex 1).